Introduction
the CFTR gene present in the patients; however, in mixed populations, such as the Brazilian one, it is not feasible yet. The ∆F508 mutation occurs due to a deletion of three bases in exon 10, resulting in the loss of the amino acid phenylalanine at position 508, which leads to a deficiency in CFTR folding and subsequently to a degradation in the rough endoplasmic reticulum. 6 The CFTR protein promotes chlorine reabsorption in sweat glands, but in CF the CFTR is absent in the epithelium or presents qualitative or quantitative changes in its level of expression; thus, chlorine is not reabsorbed, causing high concentrations of ions in sweat. This dysfunction can affect several organs, particularly those which secrete mucus, including upper and lower airways, pancreas, biliary tract, male genitalia, intestine, and sweat glands. 7 The main morbidity and mortality factor for CF is accumulation of secretion in the lungs, leading to their obstruction. Clinical presentation, disease severity, and rate of CF progression vary considerably, and some variations may occur due to presence of different combinations of mutations in the CFTR gene. Among homozygous patients for ∆F508 mutation, the severity of the pulmonary disease is variable, and the reasons for the low pulmonary correlation between genotype and phenotype are not clear; however, this mutation in homozygosis, or combined with another severe mutation, leads to the classical picture of CF. 8 Considering the importance of ∆F508 mutation in CF, due to its high frequency and severity, the aim of this study was to verify the presence of ΔF508 mutation in the CFTR gene in patients diagnosed with CF by the sweat test for sodium and chlorine and followed at the Pediatric Pneumology Outpatient Clinic of Universidade Estadual de Campinas (UNICAMP), Brazil, a referral center for the treatment of CF.
Methods
We analyzed 167 peripheral blood DNA samples from 
Results
A total of 167 samples were analyzed. Of these, the samples that had the ΔF508 mutation were amplified again to confirm the result. The results of the descriptive statistical analysis of genotypes with ΔF508 mutation are shown in Table   1 The allele frequency of ΔF508 mutation was 39.82% in the analyzed population. In a study conducted in São Paulo, Brazil, Okay et al. 2 found an allele frequency of 44.5% for ΔF508 mutation, higher to that observed in the present study. Another study of allele frequency in Minas Gerais, Brazil, and São Paulo showed lower values than those of the present study, 21.7 and 33% respectively. 11, 12 In comparison, the work of Bernardino et al., 9 (-) = absence of ΔΔF508 allele; n = sample size in absolute number of patients.
there was no statistically significant difference (p = 0.109).
Anyway, the values obtained were close, and the small variation observed between the studies can be attributed to the ethnic variation in each microregion.
Because CF is a recessive autosomal genetic disease with high morbidity and mortality rates, the inclusion of testing for CF in the neonatal screening has become extremely important. Molecular analysis is essential in order to obtain an accurate diagnosis. The molecular test performed in this study is a worldwide spread exam that, combined with neonatal screening, confers better treatment conditions and allows for genetic counseling for parents before a new pregnancy occurs. 6 Therefore, molecular analysis should begin with ΔF508 mutation, and when the patient is negative for this mutation, molecular analysis becomes complex due to the high number of existing mutations in the CFTR gene. therefore, these treatments are directed to a determined class of specific mutation or to only one mutation. 13 In conclusion, the study population showed that ΔF508 mutation was less prevalent compared with the sum of the other mutant alleles. The frequency was found to be close to that of other regions in Brazil and in the world, mainly due to the predominantly Caucasian origin of the population included in the study. In this study, allele frequency for ΔF508 mutation was 39.82%, with 55 heterozygous patients (32.9%), showing a mutated allele for ΔF508, and 39 (23.4%) homozygous patients, with two mutated alleles for ΔF508. These data corroborate the importance of using ΔF508 mutation as a diagnostic tool and mainly as a factor to be considered for a better genetic counseling.
And finally, with the development of new specific therapies for each mutation, screening for ΔF508 will be important, due to its high frequency in the population.
To determine patient's genotype for other mutations in the CFTR gene associated with CF, the analyzed population needs to be assessed by molecular analysis for other changes in the gene using different molecular techniques, such as sequencing and other methods of gene analysis.
